Anavex appoints Robert Chisholm CFO
This article was originally published in Scrip
Executive Summary
Anavex Life Sciences, a Vancouver-based pharmaceutical company developing novel drug candidates, has appointed Robert Chisholm CFO. Mr Chisholm has served on the Anavex board since May 2011 and will remain a director in addition to his new role. Mr Chisholm has been CFO of both Savary Capital and OMT since March 2011 and July 2011 respectively, and is currently CFO of TMT Resources, Emprise Capital Corp and Ripper Oil and Gas. He also serves on the board of Rare Earth Industries. Additionally, Harvey Lalach has resigned as a director and officer of the company. Mr Chisholm will serve as interim president.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.